EHA 2022 | Managing patients with T-ALL who relapse or are refractory to first-line treatment

Name: Managing patients with T-ALL who relapse or are refractory to first-line treatment
Uploaded: 2022-06-15T00:00:00Z
Duration: 48 s
Description: Ajay Vora, MD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, emphasizes the importance of better managing patients with T-cell acute lymphoblastic leukemia (T-ALL) who relapse or are refractory to first-line treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Ajay Vora • 15 Jun 2022

EHA 2022

Acute Lymphoblastic Leukemia Leukemia Rare Diseases

Ajay Vora, MD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, emphasizes the importance of better managing patients with T-cell acute lymphoblastic leukemia (T-ALL) who relapse or are refractory to first-line treatment. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.